<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl3">
 <label>Table 2</label>
 <caption>
  <p>The Candidate COVID-19 Vaccines in Clinical Evaluation.</p>
 </caption>
 <alt-text id="alttext0035">Table 2</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Name of Vaccine (Developer)</th>
    <th>Candidate Vaccine (Platform)</th>
    <th>Location</th>
    <th>Current stage (participants)</th>
    <th>Trial Quality</th>
    <th>Status (completion date)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="2">Ad5-nCoV 
     <bold>(CanSino Biological Inc./Beijing Institute of Biotechnology</bold>)
    </td>
    <td rowspan="2">Recombinant Adenovirus Type 5 Vector (Non-replicating Viral Vector)</td>
    <td rowspan="2">China</td>
    <td>Phase II (500)</td>
    <td>Safety &amp; Immune response; Randomized double-blind placebo controlled</td>
    <td>Recruiting (Jan 2021).</td>
   </tr>
   <tr>
    <td>Phase I (108)</td>
    <td>Safety; 3 different doses</td>
    <td>Completed.</td>
   </tr>
   <tr>
    <td rowspan="2">mRNA-1273 
     <bold>(Moderna/NIAID)</bold>
    </td>
    <td rowspan="2">Lipid nanoparticle-encapsulated mRNA (RNA)</td>
    <td rowspan="2">USA</td>
    <td>Phase II (IND submission)</td>
    <td>-</td>
    <td>-</td>
   </tr>
   <tr>
    <td>Phase I (
     <xref rid="bib45" ref-type="bibr">45</xref>)
    </td>
    <td>Safety &amp; immune response; 3 arms (dose 25, 100, 250 mcg)</td>
    <td>Recruiting (June 2021).</td>
   </tr>
   <tr>
    <td>PiCoVacc 
     <bold>(Sinovac Biotech)</bold>
    </td>
    <td>Inactivated SARS-CoV + Alum (Inactivated)</td>
    <td>China</td>
    <td>Phase I-II (144)</td>
    <td>Randomized double-blind single centre placebo-controlled</td>
    <td>Recruiting (Dec 2020)</td>
   </tr>
   <tr>
    <td>ChAdOx1 nCoV-19 
     <bold>(University of Oxford)</bold>
    </td>
    <td>Adenovirus vector (Non-replicating Viral Vector)</td>
    <td>UK</td>
    <td>Phase I-II (510)</td>
    <td>Single blinded randomized placebo controlled multicentreâ€™ safety and efficacy.</td>
    <td>Recruiting (May 2021)</td>
   </tr>
   <tr>
    <td>BNT162 (a1, b1, b2, c2)
     <break/>
     <bold>(BioNTehc/Fosun Pharma/Pfizer)</bold>
    </td>
    <td>Lipid nanoparticle-encapsulated -mRNA (RNA)</td>
    <td>Germany</td>
    <td>Phase I-II (196)</td>
    <td>Safety &amp; immune response; Four vaccines, dose-escalation, parallel cohort</td>
    <td>Recruiting (May 2021)</td>
   </tr>
   <tr>
    <td rowspan="2">INO-4800 
     <bold>(Inovio Pharmaceuticals, CEPI, Korean Institute of Health, International Vaccine Institute)</bold>
    </td>
    <td rowspan="2">DNA Plasmid Vaccine with electroporation (DNA)</td>
    <td rowspan="2">USA, South Korea</td>
    <td>Planning Phase II-III trials.</td>
    <td>Safety and efficacy trial</td>
    <td>-</td>
   </tr>
   <tr>
    <td>Phase I-II (
     <xref rid="bib40" ref-type="bibr">40</xref>)
    </td>
    <td>Phase I in South Korea in parallel with Phase I in the USA, completed phase I using 2 doses spaced 4 weeks apart.</td>
    <td>Results June 2020</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
